Advertisement
UK markets closed
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • CRUDE OIL

    82.51
    -0.22 (-0.27%)
     
  • GOLD FUTURES

    2,394.40
    -3.60 (-0.15%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • Bitcoin GBP

    51,081.65
    +1,858.71 (+3.78%)
     
  • CMC Crypto 200

    1,311.43
    +425.90 (+48.09%)
     
  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     
  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     

UTHR vs. ZTS: Which Stock Is the Better Value Option?

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

United Therapeutics and Zoetis are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that UTHR is likely seeing its earnings outlook improve to a greater extent. But this is just one factor that value investors are interested in.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

ADVERTISEMENT

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

UTHR currently has a forward P/E ratio of 14.10, while ZTS has a forward P/E of 31.35. We also note that UTHR has a PEG ratio of 1.56. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ZTS currently has a PEG ratio of 2.84.

Another notable valuation metric for UTHR is its P/B ratio of 2.64. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ZTS has a P/B of 16.82.

These are just a few of the metrics contributing to UTHR's Value grade of B and ZTS's Value grade of D.

UTHR stands above ZTS thanks to its solid earnings outlook, and based on these valuation figures, we also feel that UTHR is the superior value option right now.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

United Therapeutics Corporation (UTHR) : Free Stock Analysis Report

Zoetis Inc. (ZTS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research